Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics

The upcoming report from Xeris Biopharma (XERS) is expected to reveal quarterly earnings of $0.03 per share, indicating an increase of 200% compared to the year-ago period. Analysts forecast revenues of $81.43 million, representing an increase of 35.5% year over year.

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

In light of this perspective, let's dive into the average estimates of certain Xeris Biopharma metrics that are commonly tracked and forecasted by Wall Street analysts.

The consensus among analysts is that 'Product Revenue- Gvoke' will reach $26.45 million. The estimate points to a change of +13.7% from the year-ago quarter.

It is projected by analysts that the 'Product Revenue- Keveyis' will reach $43.67 million. The estimate suggests a change of +292.6% year over year.

According to the collective judgment of analysts, 'Revenue- Royalty, contract and other' should come in at $1.02 million. The estimate indicates a year-over-year change of -67.2%.

Analysts predict that the 'Revenue- Product revenue, net' will reach $81.19 million. The estimate indicates a change of +42.4% from the prior-year quarter.

Analysts expect 'Product Revenue- Recorlev' to come in at $11.07 million. The estimate indicates a year-over-year change of -51.1%.

View all Key Company Metrics for Xeris Biopharma here>>>

Xeris Biopharma shares have witnessed a change of -7% in the past month, in contrast to the Zacks S&P 500 composite's +0.6% move. With a Zacks Rank #3 (Hold), XERS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Just Released: Zacks Top 10 Stocks for 2026

Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.

From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.

Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.

See New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Xeris Biopharma Holdings, Inc. (XERS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research